Thalidomide, the notorious drug which caused horrendous birth defects in the 1950s and 1960s, is close to making a comeback as an anticancer drug. Drug firm Celgene of Warren, New Jersey, has applied to European drug authorities for permission to sell thalidomide to treat multiple myeloma, a fatal cancer of the bone marrow. In clinical trials the drug performed well against the disease. It will take Europe seven months or more to reach a verdict on the drug, which will not be prescribed to pregnant women or those considering having children.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
Life
Himalayan wolf-dog hybrids emerge as a threat to wolves and people
News
Environment
First test of CO2 removal with green sand finds no harm to marine life
News
Space
SpaceX is about to launch tallest and most powerful rocket in history
News
Environment
Cleaning up air pollution could weaken vital AMOC ocean current
News
Popular articles
Trending New Scientist articles
1
Rebooting stem cells builds aged muscles and assists injury recovery
2
Neanderthals treated a dental cavity by drilling into the tooth
3
Himalayan wolf-dog hybrids emerge as a threat to wolves and people
4
Why autism pioneer Uta Frith wants to dismantle the spectrum
5
First test of CO2 removal with green sand finds no harm to marine life
6
Where did the laws of physics come from? I think I've found the answer
7
SpaceX is about to launch tallest and most powerful rocket in history
8
Asteroid set to fly very close to Earth
9
A new tectonic plate boundary could be forming in southern Africa
10
CAR T-cell therapy bolstered by stiffening up cancer cells first
